Raising fresh capital is a familiar rhythm for early-stage biotech companies. 

For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them. 

Expert opinion is broadly optimistic on this point – bolstered by a major tick in the box from the US regulator.

The company recently announced a £4.1million equity raise, priced at 2.5p per share, a 12 per cent discount to the market price, to finance the next stage of development for its two lead assets.

They are POLB 001, targeting cancer immunotherapy induced cytokine release syndrome (CRS), and an oral glucagon like peptide 1 (GLP-1) receptor agonist designed for obesity treatment. 

The latter is a next-generation, easier-to-administer upgrade to jabs such as Ozempic and Mounjaro.

Fundraising: Poolbeg Pharma, whose executive chairman is Cathal Friel (pictured), recently announced a £4.1million equity raise

Tackling a major cancer therapy bottleneck

POLB 001 is seen as a potential game-changer. It is being developed to tackle cytokine release syndrome, a serious complication arising in patients undergoing CAR-T or bispecific antibody therapies, where an overactive immune response can lead to high fevers, low blood pressure and organ failure.

According to analysts at Shore Capital, CRS affects over 70 per cent of patients receiving such therapies and has been a major limiting factor in their wider deployment.

POLB 001 is designed as an oral preventative treatment, a notable shift from existing drugs like Roche’s injectable Actemra, which is approved for treating CRS after symptoms appear.

Broker Cavendish notes that Poolbeg’s preclinical and human challenge data already show clear suppression of key inflammatory cytokines.

If Phase 2a data confirm this, the company could be first to market with an oral CRS prophylactic, a development that Cavendish estimates could unlock a market opportunity exceeding $10billion, initially in blood cancers and potentially in solid tumours too.

The Phase 2a trial is expected to begin in the second half of this year. Big Pharma is reportedly providing the bispecific antibody therapy used in the trial at no cost, a move analysts at both Shore and Cavendish interpret as early validation of POLB 001’s commercial promise.

Crucially, the putative treatment recently received orphan drug designation from the America’s Food & Drug Administration, which significantly enhances POLB 001’s commercial appeal, especially when engaging prospective partners. This regulatory tick in the box can’t be overstated.

Seeking a slice of the weight loss boom

Poolbeg’s second programme enters another multibillion-dollar market: obesity. 

With injectable GLP-1 agonists such as Ozempic and Wegovy driving record revenues for Novo Nordisk and Eli Lilly, the race is now on to develop effective oral formulations that improve patient convenience and compliance.

Poolbeg’s answer is a proprietary microencapsulation technology licensed from AnaBio. A proof-of-concept study will begin this year at the University of Ulster, with topline data due in the first half of 2026.

ShoreCap argues that the approach could provide a differentiated product in a market forecast to reach $150billion by the early 2030s.

Cash, catalysts and credibility

Cavendish notes Poolbeg ended the first quarter of 2025 with £6.2million in cash. The current raise, assuming shareholder approval, will extend the company’s runway into 2027.

That should be enough to reach multiple clinical milestones and, ideally, deliver the data needed to secure commercial partners.

Importantly, the raise also comes with insider backing. Executive chair Cathal Friel has committed to invest £100,000, providing a measure of confidence in the company’s direction.

Execution

Still, investors should keep their eyes on execution. While both POLB 001 and the GLP-1 asset are tackling real clinical problems with significant market potential, they remain pre-revenue and subject to trial risk.

Poolbeg’s ability to translate promise into partnerships will be the key driver of any future valuation shift.

Cavendish maintains a 19p target on the shares, implying significant upside from the current 2.9p.

But for that to materialise, the next 12 to 18 months will need to deliver more than just well-funded plans. They will need hard data.

For all the latest small- and mid-cap news go to www.proactiveinvestors.co.uk.

DIY INVESTING PLATFORMS

AJ Bell

AJ Bell

Easy investing and ready-made portfolios

Hargreaves Lansdown

Hargreaves Lansdown

Free fund dealing and investment ideas

interactive investor

interactive investor

Flat-fee investing from £4.99 per month

InvestEngine

InvestEngine

Account and trading fee-free ETF investing

Trading 212

Trading 212

Free share dealing and no account fee

Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.

Compare the best investing account for you